Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} The combination of lirilumab and...
-
SALT LAKE CITY, Oct. 07, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that four poster presentations...
-
PRESS RELEASE - Friday, 7 October 2016, 07:00 CEST THREE IDYLLA(TM) TEST PERFORMANCE STUDIES TO BE PRESENTED AT ESMO ONCOLOGY CONFERENCE Mechelen, Belgium, 7 October 2016 - Biocartis Group NV...
-
PERSBERICHT - Vrijdag, 7 oktober 2016, 07:00 CEST PRESENTATIE DRIE PERFORMANTIESTUDIES OVER IDYLLA(TM) TESTEN OP ESMO ONCOLOGIE CONFERENTIE Mechelen, België, 7 oktober 2016 - Biocartis Groep NV...
-
- Single-Agent Selinexor Demonstrates Robust Clinical Benefit and Favorable Tolerability in Patients with Heavily Pre-treated Gynecologic Cancers - - 49% Disease Control Rate Observed in Ovarian...
-
BURLINGAME, Calif., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
-
MONTREAL, QC--(Marketwired - October 03, 2016) - Angiochem, a biotechnology company developing peptide drug conjugates uniquely capable of crossing the blood-brain barrier, announced it will make a...
-
Pressmeddelande, Linköping den 30 september 2016 - Styrelsen i IT- och medicinteknikbolaget Sectra AB (STO: SECT B) har beslutat att flytta fram publiceringen av bolagets halvårsrapport för perioden...
-
Linköping, Sweden, September 30, 2016 – The Board of Directors of IT and medical technology company Sectra AB (STO: SECT B) has decided to postpone the publication of the company’s six-month report...
-
WEST LAFAYETTE, Ind., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for...